Winston Pharmaceuticals WPHM · USD

Its shares trade under the ticker WPHM. It has been listed since 23 February 2006. In the fiscal year to 31 December 2009, it reported revenue of $1.4m and a net loss of $2.7m. At that date it held total assets of $1.7m and shareholders' equity of $488,571.

Winston Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the discovery and development of products for pain management. The company is headquartered in Vernon Hills, Illinois. The company went IPO on 2006-02-23. The firm discovers, develops and commercializes therapeutics for managing and alleviating pain. The firm's late stage candidates include products for the treatment of episodic cluster headache, chronic migraine headache, osteoarthritis, rheumatoid arthritis, neuropathic pain, and pain and inflammation in inflammatory bowel disease. The firm is developing Civamide, which is a transient receptor potential channels vanilloid-1 (TRPV-1) modulator in different dosage forms for several different pain indications. The firm's other products are under development for the treatment of headache and neuropathic and rheumatological pain.

Figures and description from our data supplier, not checked against the company's own report.

• Robert YollesChairman of the Board, since 2008
• Dr. Joel BernsteinPresident, Chief Executive Officer, Director, since 2008$506,900
• Dr. Jeffrey BernsteinPresident, Chief Executive Officer
• Mr. David StarrChief Financial Officer, Vice President, Secretary$375,030
• Dr. Scott PhillipsSenior Vice President - Scientific Affairs, Director, since 2008$381,588
• Dr. Neal PenneysDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.